1. Home
  2. AMGN vs GEV Comparison

AMGN vs GEV Comparison

Compare AMGN & GEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AMGN
  • GEV
  • Stock Information
  • Founded
  • AMGN 1980
  • GEV 2023
  • Country
  • AMGN United States
  • GEV United States
  • Employees
  • AMGN N/A
  • GEV N/A
  • Industry
  • AMGN Biotechnology: Biological Products (No Diagnostic Substances)
  • GEV
  • Sector
  • AMGN Health Care
  • GEV
  • Exchange
  • AMGN Nasdaq
  • GEV NYSE
  • Market Cap
  • AMGN 157.5B
  • GEV 132.9B
  • IPO Year
  • AMGN N/A
  • GEV N/A
  • Fundamental
  • Price
  • AMGN $292.51
  • GEV $559.63
  • Analyst Decision
  • AMGN Hold
  • GEV Buy
  • Analyst Count
  • AMGN 20
  • GEV 28
  • Target Price
  • AMGN $322.30
  • GEV $471.57
  • AVG Volume (30 Days)
  • AMGN 2.7M
  • GEV 3.0M
  • Earning Date
  • AMGN 08-05-2025
  • GEV 07-23-2025
  • Dividend Yield
  • AMGN 3.25%
  • GEV 0.18%
  • EPS Growth
  • AMGN 56.16
  • GEV N/A
  • EPS
  • AMGN 10.94
  • GEV 6.93
  • Revenue
  • AMGN $34,126,000,000.00
  • GEV $35,707,000,000.00
  • Revenue This Year
  • AMGN $7.73
  • GEV $6.87
  • Revenue Next Year
  • AMGN $1.78
  • GEV $8.98
  • P/E Ratio
  • AMGN $26.78
  • GEV $80.84
  • Revenue Growth
  • AMGN 15.56
  • GEV 6.03
  • 52 Week Low
  • AMGN $253.30
  • GEV $150.01
  • 52 Week High
  • AMGN $346.85
  • GEV $560.38
  • Technical
  • Relative Strength Index (RSI)
  • AMGN 52.53
  • GEV N/A
  • Support Level
  • AMGN $291.25
  • GEV N/A
  • Resistance Level
  • AMGN $302.38
  • GEV N/A
  • Average True Range (ATR)
  • AMGN 7.04
  • GEV 0.00
  • MACD
  • AMGN 0.55
  • GEV 0.00
  • Stochastic Oscillator
  • AMGN 66.26
  • GEV 0.00

About AMGN Amgen Inc.

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

About GEV GE VERNOVA INC

GE Vernova is a global leader in the electric power industry, with products and services that generate, transfer, convert, and store electricity. The company has three business segments: power, wind, and electrification. Power includes gas, nuclear, hydroelectric, and steam technologies, providing dispatchable power. The wind segment includes wind generation technologies, inclusive of onshore and offshore wind turbines and blades. Electrification includes grid solutions, power conversion, electrification software, and solar and storage solutions technologies required for the transmission, distribution, conversion, and storage of electricity from the point of generation to point of consumption.

Share on Social Networks: